
Boehringer Ingelheim's pharmaceutical R&D capabilities are globally leading in the industry.
Boehringer Ingelheim's pharmaceutical R&D capabilities are globally leading in the industry. The company will launch new products or new indications of existing products in fields such as cardiovascular and metabolic, respiratory, oncology, immunology, central nervous, and retinal disease to meet the needs of Chinese patients.
Boehringer Ingelheim's pharmaceutical R&D capabilities are globally leading in the industry.